Jefferies Financial Group Inc. purchased a new stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 93,400 shares of the company's stock, valued at approximately $3,401,000. Jefferies Financial Group Inc. owned 0.16% of Harmony Biosciences as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently modified their holdings of HRMY. Chase Investment Counsel Corp acquired a new stake in shares of Harmony Biosciences in the 2nd quarter worth $1,820,000. CX Institutional boosted its position in shares of Harmony Biosciences by 19.7% during the 4th quarter. CX Institutional now owns 275,809 shares of the company's stock valued at $10,321,000 after acquiring an additional 45,376 shares during the last quarter. Aurora Investment Counsel purchased a new stake in shares of Harmony Biosciences in the second quarter valued at about $2,372,000. Sanctuary Advisors LLC purchased a new stake in shares of Harmony Biosciences in the first quarter valued at about $1,030,000. Finally, Convergence Investment Partners LLC acquired a new stake in Harmony Biosciences during the fourth quarter worth about $961,000. 86.23% of the stock is owned by hedge funds and other institutional investors.
Harmony Biosciences Trading Down 1.7%
HRMY opened at $39.21 on Friday. Harmony Biosciences Holdings, Inc. has a 52 week low of $25.52 and a 52 week high of $40.87. The company has a quick ratio of 3.45, a current ratio of 3.48 and a debt-to-equity ratio of 0.13. The business has a fifty day simple moving average of $36.88 and a 200-day simple moving average of $32.82. The firm has a market cap of $2.28 billion, a P/E ratio of 12.73, a P/E/G ratio of 0.37 and a beta of 0.96.
Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $1.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.96 by $0.32. Harmony Biosciences had a return on equity of 20.06% and a net margin of 18.88%.The firm had revenue of $261.28 million for the quarter, compared to the consensus estimate of $250.77 million. During the same quarter in the previous year, the business earned $0.92 EPS. The company's quarterly revenue was up 30.3% compared to the same quarter last year. On average, equities analysts expect that Harmony Biosciences Holdings, Inc. will post 3.77 earnings per share for the current year.
Analysts Set New Price Targets
Several research analysts recently weighed in on HRMY shares. HC Wainwright reiterated a "buy" rating and issued a $55.00 price objective on shares of Harmony Biosciences in a research report on Thursday, July 16th. Wolfe Research initiated coverage on Harmony Biosciences in a research report on Wednesday. They set an "outperform" rating and a $60.00 price objective for the company. Zacks Research lowered shares of Harmony Biosciences from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 11th. Truist Financial upped their target price on shares of Harmony Biosciences from $29.00 to $34.00 and gave the company a "hold" rating in a research report on Wednesday, August 5th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and set a $39.00 target price on shares of Harmony Biosciences in a research note on Wednesday, August 5th. Five research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Harmony Biosciences presently has an average rating of "Hold" and an average price target of $47.11.
Get Our Latest Research Report on HRMY
Harmony Biosciences Company Profile
(
Free Report)
Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company's mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.
The company's flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Harmony Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harmony Biosciences wasn't on the list.
While Harmony Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
